Q&A with Rao Tatapudy, Catalent - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Rao Tatapudy, Catalent
A Q&A with Rao Tatapudy, vice-president of scientific affairs at Catalent, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 140

PharmTech:



What is the biggest industry challenge you're now facing?

Tatapudy:

The productivity and efficiency of internal drug development have become big challenges in the industry. These challenges arise from the large size of a few Big Pharma companies (which results from consolidation), the emergence of several large generic-drug players, long approval times for both branded and generic products, and a short patent life for new drugs. This situation is an opportunity for global drug-development and delivery companies that support the pharmaceutical industry. By offering support for a product's entire life cycle, including preformulation, product development, clinical supplies, commercialization, analytical services, packaging services, and regulatory support, these companies can position themselves to succeed in the current environment.

PharmTech:

Do you see a new industry trend emerging?

Tatapudy:

Yes. Big Pharma is struggling with extensive talent on hand and limited product-development budgets, partly because of mergers and acquisitions, and partly because fewer and fewer new drug applications are being filed each year. On the other hand, global drug-development and delivery companies are extremely enthusiastic about the prospects for growth and innovation and have expanded their horizons to serve the entire industry across most dosage forms. In particular, because a large majority of new molecules in development are BCS class II and IV compounds with significant bioavailability challenges, highly specialized expertise in drug development, delivery, and manufacturing will be needed, and this situation will require drug innovators to work closely with specialty drug delivery companies such as Catalent.

PharmTech:

What is the most common demand your clients are currently making of you?

Tatapudy:

Our customers approach us for more products, better treatments, reliably supplied. Many customers come to Catalent for help in solving their bioavailability, solubility, and permeability challenges.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here